HPV Vaccination Eliminates Cervical Cancer Deaths in UK Young Women

New research indicates that cervical cancer mortality rates among young women in the UK have dropped significantly following the introduction of the nationwide HPV vaccination program. A pioneering study reveals that among vaccinated women aged 20 to 24, zero deaths were recorded during the five most recent years, a stark contrast to the 23.1 deaths that epidemiological models predicted would occur in this cohort. This outcome suggests a 100 per cent reduction in deaths for this specific age group.

The study, published in *The Lancet* and conducted by researchers at Queen Mary University of London, analyzed mortality data from England spanning 2001 to 2024. Lead author Professor Peter Sasieni stated, "For more than two decades, our team has been building evidence to show that HPV causes cervical cancer and that vaccination prevents infections, precancerous changes, and the disease itself." The findings highlight that the vaccine has already prevented approximately 200 cervical cancer deaths in England, with projections suggesting this number will rise as more girls receive the immunization.

Human papillomavirus (HPV) is responsible for roughly 95 per cent of cervical cancer cases. The virus causes cancer when abnormal cells develop in the cervix lining, eventually forming a tumour. While the UK recommends the HPV vaccine for girls aged 12 to 13 and high-risk individuals, current uptake levels remain below the threshold required to eradicate the disease as a public health issue. Currently, vaccination rates for girls in the UK by age 15 range between 76 and 86 per cent, falling short of the World Health Organisation's (WHO) target of 90 per cent.

Data from the study showed that in earlier cohorts, where vaccination was offered up to age 18, death rates in the 20-24 age group fell by approximately 80 per cent. Modelling estimates indicate a relative risk reduction of 100 per cent for vaccinated women aged 24 to 29, with a nearly two-thirds reduction for those aged 30 to 34. Experts caution that current figures likely represent only a fraction of the vaccine's potential benefit, as the number of prevented deaths is expected to increase exponentially over the next two decades as vaccinated cohorts age.

Michelle Mitchell, chief executive of Cancer Research UK, described the findings as an "incredible milestone." She noted that while the vaccine is effective at stopping cervical cancer before it begins, recent declines in uptake threaten this progress. She emphasized that the government and health systems must take urgent, targeted action to reach communities with low vaccination rates. Caroline Temmink, director of vaccination at the NHS, added that the goal is to inform this generation that cervical cancer should no longer be a risk. She affirmed that the vaccine is safe and effective, urging all eligible individuals to accept the offer when invited.

The WHO's global strategy aims to vaccinate 90 per cent of girls by age 15, screen 70 per cent of women, and treat 90 per cent of those with cervical disease by 2030. Achieving these targets is projected to prevent 62 million deaths and 74 million new cases globally by 2120. However, in the UK, declining screening and vaccination rates are currently contributing to approximately 685 cervical cancer deaths annually in England alone.